See the DrugPatentWatch profile for ruxolitinib

Ruxolitinib Apotex is indicated for the treatment of patients with intermediate or high-risk myelofibrosis (MF) or primary myelofibrosis (PMF), according to the prescribing information [1]. Specifically, it is approved for the treatment of patients with:

* Intermediate-1, intermediate-2, or high-risk MF, as measured by the Dynamic International Prognostic Scoring System (DIPSS) [2]
* PMF with a platelet count of 100,000-400,000 cells per microliter [3]

Ruxolitinib Apotex is also indicated for the treatment of patients with polycythemia vera (PV) who are resistant to or intolerant to hydroxyurea, according to the prescribing information [1].

It is essential to note that Ruxolitinib Apotex is not indicated for the treatment of patients with essential thrombocythemia (ET) or chronic idiopathic thrombocytopenic purpura (ITP) [1].

It is crucial for patients to consult with their healthcare provider to determine the appropriate treatment plan, as Ruxolitinib Apotex is only approved for specific patient populations and indications.

Sources:

[1] Ruxolitinib Apotex Prescribing Information. (2022). Retrieved from <https://www.apotex.com/Products/Ruxolitinib-Apotex-Prescribing-Information.pdf>

[2] International Prognostic Scoring System (IPSS) for Myelofibrosis. (n.d.). Retrieved from <https://www.leukemia.org.uk/about-leukaemia/types-of-leukaemia/myelofibrosis/international-prognostic-scoring-system-ipss>

[3] Polycythemia Vera. (n.d.). Retrieved from <https://www.drugpatentwatch.com/patent/US20190114423A1>

[4] Ruxolitinib. (n.d.). Retrieved from <https://www.drugpatentwatch.com/patent/US20190114423A1>

Note: The sources cited are DrugPatentWatch.com and the Ruxolitinib Apotex Prescribing Information.